Why Migraines Are More Than Just Headaches

Imagine sitting in a quiet, dimly lit room, forced to step away from your day because every ray of light feels like a sharp glare and even low sounds trigger a surge of discomfort. For millions of people, this is a regular reality caused by a migraine.

Migraine attacks can disrupt everyday life, causing intense pain alongside nausea and sensitivity to light and sound.

While many people think of a migraine as simply a severe headache, it is actually a complex neurological condition that affects how the brain processes sensory information. Beyond intense head pain, an attack can bring on nausea, extreme sensitivity to light and sound, and difficulty concentrating, making routine tasks nearly Impossible. Understanding what actually causes these symptoms reveals that a migraine is a whole-body neurological event.

At its core, a migraine is a complex neurovascular disorder rather than a simple vascular tension headache. During an attack, a primary driver of symptoms is altered brain excitability and nerve signaling. Researchers have identified a process called cortical spreading depression, a slow-moving wave of electrical depolarization across the cerebral cortex, that temporarily disrupts normal brain cell activity. This electrical wave can trigger sensory disturbances, such as visual aura, and stimulate the trigeminovascular system, a

Migraine involves changes in brain activity and nerve signaling that contribute to pain and other symptoms.

major pain pathway connecting the brainstem to the blood vessels lining the protective coverings of the brain (the meninges). When this nerve network is activated, it releases neuropeptides like calcitonin gene-related peptide (CGRP), inducing localized Inflammation and dilating blood vessels. This cascade sends continuous pain signals back to the brainstem and higher sensory regions, amplifying the throbbing sensation and turning ordinary physiological signals into intense pain.

Understanding these underlying brain mechanisms helps explain why migraines present such a wide variety of symptoms beyond pain itself. As the electrical wave of cortical spreading depression moves across the cerebral cortex, it temporarily alters how sensory information is processed. This sensory processing dysfunction frequently manifests as aura -- a temporary neurological symptom that can include visual

Migraine aura can cause temporary visual disturbances, including zigzag patterns and flickering lights.

disturbances like flickering lights, jagged lines, or blind spots, as well as tingling sensations in the face or hands. Furthermore, the activation of central brainstem structures disrupts normal sensory gating, leaving the brain unable to properly filter out ambient stimuli. Consequently, routine environmental inputs like normal room lighting, background noise, or mild odors become intensely overwhelming, leading to the severe photophobia (light sensitivity), phonophobia (sound sensitivity), and nausea that characterize a full-scale migraine attack.

Because migraine attacks involve widespread changes across the central nervous system, symptoms often begin long before the head pain starts and linger well after it subsides. Clinicians divide a full migraine attack into four distinct phases: the prodrome, aura, headache, and postdrome. During the prodrome -- which can occur up to 24 or 48 hours before the main pain hits -- subtle shifts in the hypothalamus can cause mood changes, food

Migraine symptoms can begin before the headache and continue into recovery, when fatigue and difficulty concentrating may persist.

cravings, neck stiffness, and frequent yawning. Following the headache phase, many individuals experience the postdrome, often described as a "migraine hangover." During this final stage, lingering neurochemical Imbalances leave people feeling drained, confused, and fatigued for up to two days. Recognizing these distinct phases highlights how migraines ripple across the entire nervous system, affecting a person's cognitive function and energy levels far beyond the duration of the pain itself.

Understanding the complex biological chain behind migraines has transformed how researchers and doctors approach treatment. Historically, people relied primarily on general painkillers or medications called triptans, which work by constricting blood vessels to relieve pain. However, recent advances in neurobiology have led to targeted therapies specifically designed around the brain's signaling molecules. The

Targeted migraine therapies, including treatments that act on the CGRP pathway, have expanded options for managing migraine.

development of CGRP inhibitors, medications that block calcitonin gene-related peptide or its receptors, directly targets the neuropeptides responsible for neurogenic inflammation and pain signaling during an attack. By shifting the focus from simply dulling symptoms to intercepting the specific neurochemical triggers, these modern therapies offer a clearer path to intercepting the specific neurochemical triggers, these modern therapies offer a clearer path toward prevention and relief, validating migraine as a distinct and manageable neurological disorder.

Viewing migraines as a complex neurological condition rather than just an ordinary headache is crucial for both proper care and empathy. By looking closely at the brain -- from the electrical wave of cortical spreading depression to the systemic phases that precede and follow the pain -- it becomes clear how deeply an attack impacts the entire body. Advances in targeted treatments, such as CGRP Inhibitors, underscore the progress made when medical science addresses the specific mechanisms of neurogenic inflammation. Ultimately, recognizing the true depth of migraines helps destigmatize the condition, encouraging those affected to seek specialized care while opening the door to more effective, evidence-based therapies.

References

1. Cleveland Clinic. “CGRP Inhibitors Treat Migraine Headaches. They’re the First Medications Developed to Treat and Prevent Migraines Directly..” Cleveland Clinic, 27 Jan. 2025, https://my.clevelandclinic.org/health/treatments/cgrp-inhibitors. Accessed 18 Oct. 2026.

2. Gibb, Vera. “American Headache Society Position Statement: Calcitonin Gene-Related Peptide (CGRP) Inhibitors Should Now Be Considered a First-Line Option for Migraine Prevention.” Association of Migraine Disorders, 26 Apr. 2024, https://www.migrainedisorders.org/ahs-statement-cgrp/. Accessed 18 Oct. 2026.

3. Hill, Arren, et al. “Metabolic Pathophysiology of Cortical Spreading Depression: A Review.” Brain Sciences, vol. 14, no. 10, Multidisciplinary Digital Publishing Institute, Oct. 2024, pp. 1026–26, https://doi.org/10.3390/brainsci14101026.

4. Noseda, Rodrigo, and Rami Burstein. “Migraine Pathophysiology: Anatomy of the Trigeminovascular Pathway and Associated Neurological Symptoms, Cortical Spreading Depression, Sensitization, and Modulation of Pain.” Pain, vol. 154, no. Supplement 1, Ovid Technologies (Wolters Kluwer Health), Dec. 2013, pp. S44–53, https://doi.org/10.1016/j.pain.2013.07.021.

5. “Proposed Phases of a Migraine Attack - Neurotorium.” Neurotorium, 22 Mar. 2024, https://neurotorium.org/image/proposed-phases-of-a-migraine-attack/. Accessed 18 Oct. 2026.

6. “The Timeline of a Migraine Attack | American Migraine Foundation.” American Migraine Foundation, 18 Jan. 2018, https://americanmigrainefoundation.org/resource-library/timeline-migraine-attack/. Accessed 18 Oct. 2026.

Assessed and Endorsed by the MedReport Medical Review Board